Facial Filler InjectionsPhase 2NCT06665594
Effect of TXA on Reducing Bruising After Filler Injection
A Phase 2 study testing Hyaluronic Acid (HA) and Tranexamic Acid (TXA) in people with Facial Filler Injections and Hyaluronic Acid, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?… Read more about this study
- Who is it for?
- Ages 18 to 89 yearsHealthy volunteers can take part
- Conditions the study is for
- Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
- What is being tested?
- Hyaluronic Acid (HA) and Tranexamic Acid (TXA)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Dec 2025to Nov 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age equal to or greater than 18 but less than or equal to 89 years.
- Participants interested in facial filler (HA) injection.
- English speaking.
Who cannot join
- Minors or under the age of 18
- Participant over the age of 89
- Pregnant or breast-feeding women
- Individuals unable to give consent due to another condition such as impaired decision-making capacity.
- Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
- Participants undergoing unilateral facial filler (HA) injection
Show all 13Show fewer
- Participants with history of hypersensitivity to TXA or any of the other ingredients
- Participants that are on current therapeutic anticoagulation therapy and aspirin use
- Participants with stage 2 or greater renal failure
- Participants on hemodialysis or peritoneal dialysis
- History of diabetes or seizures
- Current tobacco smokers
- Acquired defective color vision
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Wisconsin - Madison
Madison, Wisconsin, 53705
Daniel Cho, MD, PhD, 608-263-7502, chod@surgery.wisc.edu
Daniel Y Cho, MD, PhD
About this study
Official title: Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:
- Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?
Participants will receive the study medication along with the standard facial filler injection and complete surveys.
Read the detailed description
The overall purpose of this study is to evaluate the safety and efficacy of co-administration of TXA with HA in reducing swelling, bruising and pain after facial injection. Researchers will do this by comparing HA to HA+TXA in participants undergoing facial filler injections. Participants undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Therefore, researchers have designed this as a half face study. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Researchers will then assess swelling, bruising, pain, and overall satisfaction using participant self-reported surveys, physician surveys, and review of medical records.
- Conditions
- Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
- Being tested
- Hyaluronic Acid (HA), Tranexamic Acid (TXA), Saline (placebo)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hyaluronic Acid (HA)Procedure or surgery
Injectable gel
Tranexamic Acid (TXA)Drug
Injection of TXA
Saline (placebo)Drug
Injection of saline
| Study group | Role | What they receive |
|---|---|---|
| Facial Filler Injection | Experimental | TXA plus HA injection in half of face, saline plus HA injection on other half of face Receives: Procedure: Hyaluronic Acid (HA); Drug: Tranexamic Acid (TXA); Drug: Saline (placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intensity of bruising on TXA + HA half of face
Participants will score the intensity of bruising on a 5-point Likert scale, where 1 = no bruising and 5 = severe bruising.
Measured: Post-procedure day 7
Intensity of bruising on saline + HA half of face
Participants will score the intensity of bruising on a 5-point Likert scale, where 1 = no bruising and 5 = severe bruising.
Measured: Post-procedure day 7
Duration of bruising on TXA + HA half of face
Participants will indicate on what day their bruising disappeared, or whether it is still there.
Measured: Post-procedure day 7
Duration of bruising on saline + HA half of face
Participants will indicate on what day their bruising disappeared, or whether it is still there.
Measured: Post-procedure day 7
Secondary outcomes (10)
Intensity of bruising on TXA + HA half of face
Participants will score the intensity of bruising on a 5-point Likert scale, where 1= no bruising and 5= severe bruising.
Measured: Post-procedure day 1
Intensity of bruising on saline + HA half of face
Participants will score the intensity of bruising on a 5-point Likert scale, where 1= no bruising and 5= severe bruising.
Measured: Post-procedure day 1
Duration of bruising on TXA + HA half of face
Participants will indicate on what day their bruising disappeared, or whether it is still there.
Measured: Post-procedure day 1
Duration of bruising on saline + HA half of face
Participants will indicate on what day their bruising disappeared, or whether it is still there.
Measured: Post-procedure day 1
Intensity of swelling on TXA + HA half of face
Participants will score the intensity of swelling on a 5-point Likert scale, where 1 = no swelling and 5 = severe swelling.
Measured: Post-procedure days 1 and 7
Intensity of swelling on saline + HA half of face
Participants will score the intensity of swelling on a 5-point Likert scale, where 1 = no swelling and 5 = severe swelling.
Measured: Post-procedure days 1 and 7
Intensity of pain on TXA + HA half of face
Participants will score the intensity of pain on a 10-point Likert scale, where 0 = no pain and 10 = worst pain possible.
Measured: Post-procedure days 1 and 7
Intensity of pain on saline + HA half of face
Participants will score the intensity of pain on a 10-point Likert scale, where 0 = no pain and 10 = worst pain possible.
Measured: Post-procedure days 1 and 7
Overall satisfaction with aesthetic of TXA + HA half of face
Participants will rate their overall satisfaction on a 5-point Likert scale where 1 = completely dissatisfied and 5 = completely satisfied
Measured: Post-procedure days 1 and 7
Overall satisfaction with aesthetic of saline + HA half of face
Participants will rate their overall satisfaction on a 5-point Likert scale where 1 = completely dissatisfied and 5 = completely satisfied
Measured: Post-procedure days 1 and 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2024
- Study start5 Dec 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Facial Filler InjectionsStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Daniel Cho, MD, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06665594
- Sponsor's protocol ID
- 2024-1103
- Other IDs
- A539730, Protocol Version 3/13/26
- Status last verified
- Jul 2026
- First submitted
- 29 Oct 2024
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study
- ClinicalTrials.gov ID
- NCT06665594
- Acronym / sponsor ID
- 2024-1103
- Conditions
- Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- 5 Dec 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 30 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:
- Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?
Participants will receive the study medication along with the standard facial filler injection and complete surveys.
Detailed description
The overall purpose of this study is to evaluate the safety and efficacy of co-administration of TXA with HA in reducing swelling, bruising and pain after facial injection. Researchers will do this by comparing HA to HA+TXA in participants undergoing facial filler injections. Participants undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Therefore, researchers have designed this as a half face study. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Researchers will then assess swelling, bruising, pain, and overall satisfaction using participant self-reported surveys, physician surveys, and review of medical records.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Facial Filler Injection | Experimental | Procedure: Hyaluronic Acid (HA), Drug: Tranexamic Acid (TXA), Drug: Saline (placebo)TXA plus HA injection in half of face, saline plus HA injection on other half of face |
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age equal to or greater than 18 but less than or equal to 89 years.
- Participants interested in facial filler (HA) injection.
- English speaking.
Key exclusion criteria (13 listed)
- Minors or under the age of 18
- Participant over the age of 89
- Pregnant or breast-feeding women
- Individuals unable to give consent due to another condition such as impaired decision-making capacity.
- Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hyaluronic Acid (HA)Injectable gel | Procedure or surgery | Facial Filler Injection |
| Tranexamic Acid (TXA)Injection of TXA | Drug | Facial Filler Injection |
| Saline (placebo)Injection of saline | Drug | Facial Filler Injection |
Primary outcome
Intensity of bruising on TXA + HA half of face
Time frame: Post-procedure day 7
Participants will score the intensity of bruising on a 5-point Likert scale, where 1 = no bruising and 5 = severe bruising.
Intensity of bruising on saline + HA half of face
Time frame: Post-procedure day 7
Participants will score the intensity of bruising on a 5-point Likert scale, where 1 = no bruising and 5 = severe bruising.
Duration of bruising on TXA + HA half of face
Time frame: Post-procedure day 7
Participants will indicate on what day their bruising disappeared, or whether it is still there.
Duration of bruising on saline + HA half of face
Time frame: Post-procedure day 7
Participants will indicate on what day their bruising disappeared, or whether it is still there.
10 secondary outcomes
Intensity of bruising on TXA + HA half of face
Time frame: Post-procedure day 1
Intensity of bruising on saline + HA half of face
Time frame: Post-procedure day 1
Duration of bruising on TXA + HA half of face
Time frame: Post-procedure day 1
Duration of bruising on saline + HA half of face
Time frame: Post-procedure day 1
Intensity of swelling on TXA + HA half of face
Time frame: Post-procedure days 1 and 7
Intensity of swelling on saline + HA half of face
Time frame: Post-procedure days 1 and 7
Intensity of pain on TXA + HA half of face
Time frame: Post-procedure days 1 and 7
Intensity of pain on saline + HA half of face
Time frame: Post-procedure days 1 and 7
Overall satisfaction with aesthetic of TXA + HA half of face
Time frame: Post-procedure days 1 and 7
Overall satisfaction with aesthetic of saline + HA half of face
Time frame: Post-procedure days 1 and 7
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Facial Filler Injections
Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Post-COVID-19 Condition, Ulcerative Colitis
RecruitingPhase 4
Evaluation of Filler Injection for Chin Profile Enhancement
Chin Regression, Chin Asymmetry
Active, not recruiting
Clinical Investigation for Evaluating the Safety and Efficacy of JTM102 to Mid Face Volume Deficiency
Mid Face Volume Deficit
Active, not recruiting
Evaluation of Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling
Dermal Fillers, Cheek Augmentation
Active, not recruiting
Evaluation of Safety of Filler Injection in Subcutaneous Tissues
Face Volume Deficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniel Cho, MD, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Hyaluronic Acid (HA) and Tranexamic Acid (TXA) in people with Facial Filler Injections and Hyaluronic Acid, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel Cho, MD, PhD (608-263-6330, chod@surgery.wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intensity of bruising on TXA + HA half of face (time frame: Post-procedure day 7). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.